Merck Signs Voluntary Licensing Deals for Experimental HIV Prevention Pill

Merck has signed a series of voluntary licensing agreements that will allow generic drugmakers in lower-income countries to manufacture its experimental oral pill for HIV pre-exposure prophylaxis, or PrEP, the company said, in a move meant to speed access to the drug in the countries carrying the world's heaviest HIV burden even before the medicine has cleared regulatory review.

Voluntary licensing is a legal arrangement in which a patent holder — in this case Merck — grants outside manufacturers the right to produce and sell a version of its product, typically in a defined list of countries and in exchange for royalty payments, without requiring litigation or compulsory government intervention. The approach lets originator companies retain some commercial return while allowing lower-cost versions to reach markets they do not prioritize commercially.

The deals apply specifically to countries with the highest rates of new HIV infections, many of them in sub-Saharan Africa, where health systems have long relied on donor-funded programs to distribute prevention and treatment drugs. Public health researchers have said that broadening the range of affordable PrEP options is important because daily pill regimens and long-acting alternatives suit different patients depending on cost, stigma and access to clinics.

The strategy echoes, in general terms, licensing arrangements that reshaped access to HIV medicines two decades ago, when generic manufacturers — particularly in India — began producing lower-cost versions of antiretroviral therapies under negotiated agreements and patent pools, dramatically cutting treatment costs in the countries that needed them most. A similar model was later used for direct-acting antiviral drugs that cure hepatitis C, where voluntary licenses helped generic versions reach patients in dozens of countries at a fraction of the price charged in wealthier markets.

Under such arrangements, the mechanics are usually similar: a manufacturer applies to be added as a sublicensee, agrees to supply only the designated set of countries, and pays a royalty — often a low single-digit percentage of sales — back to the original patent holder. Multilateral bodies such as the Medicines Patent Pool have historically helped coordinate these deals, though Merck's announcement did not specify whether the pool was involved in this instance.

Merck's pill remains an experimental product. It has not yet received approval from the U.S. Food and Drug Administration or other major regulators, and the company has not disclosed a specific timeline for when that review might conclude. Licensing agreements signed now are intended to let generic manufacturers begin preparing production lines and regulatory filings in parallel with the ongoing approval process, rather than waiting until after a decision is made.

That head start carries real logistical value in global health, where the gap between a drug's approval in wealthy markets and its arrival in lower-income countries has historically stretched for years. But it also means significant uncertainty remains: final trial results, dosing guidance and safety data have not been fully reviewed by regulators, and production scale-up depends on manufacturing capacity that is not yet built out.

If approved, the pill would join a small but growing set of HIV prevention options that already includes daily oral drugs such as Truvada and Descovy and long-acting injectable options that require dosing only every few months. Health officials have said an oral option manufactured widely and cheaply could appeal to patients who prefer not to visit a clinic for injections, or in settings where injectable cold-chain logistics are difficult to maintain.

The licensing announcement comes as global HIV prevention funding faces pressure in several donor countries, prompting public health groups to look for ways to keep prevention costs down even as aid budgets tighten. Analysts tracking the space say the ultimate impact of the deals will depend less on the agreements themselves than on how quickly generic manufacturers can actually bring product to market once — and if — regulators sign off.

For now, Merck has framed the licensing deals as a preparatory step rather than a finished solution, with company statements emphasizing that the goal is readiness: positioning generic supply chains to move quickly the moment the pill clears regulatory hurdles, in a bid to avoid the years-long access delays that have accompanied past HIV drug rollouts.